# US 2013/0156773 A1 · Lung regeneration using cord blood-derived hematopoietic stem cells > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2013/0156773 A1 - Document ID: US20130156773A1 - Status: Published application - Kind: A1 - Application number: 13/805,003 - Filed: 2011-06-17 - Published: 2013-06-20 - Earliest claimed: 2010-06-18 - Assignees: Women & Infants Hospital of Rhode Island - Inventors: Monique E. Depaepe - Web page: https://patentgrep.com/patent/US20130156773A1 ## CPC - A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42) - A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells - A61P 11/00: Drugs for disorders of the respiratory system - A61P 35/00: Antineoplastic agents - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Described herein are novel approaches for regenerating injured or defective lung epithelium for the treatment of respiratory disorders using, in part, cord blood-derived hematopoietic stem cells. The methods and uses described herein relate to the administration of or use of hematopoietic stem cells, specifically those isolated or enriched from umbilical cord blood, to a subject in need thereof having a respiratory disorder, such as BPD, or any disorder characterized by insufficient or defective or injured lung epithelium or lung vasculature. ## Claims ### Claim 1 A method for treating or preventing a lung disorder in a subject in need thereof, comprising administering a therapeutically effective amount of a population of isolated or enriched umbilical cord blood derived hematopoietic stem cells to said subject. ### Claim 2 A method for repairing or reconstituting or generating pulmonary epithelium in a subject in need thereof, comprising administering a population of isolated or enriched umbilical cord blood derived hematopoietic stem cells to said subject. ### Claim 3 A method for repairing or reconstituting or generating pulmonary vasculature or pulmonary endothelium in a subject in need thereof, comprising administering a population of isolated or enriched umbilical cord blood derived hematopoietic stem cells to said subject. ### Claim 4 A method for repairing or reconstituting pulmonary alveoli in a subject in need thereof, comprising administering a population of isolated or enriched umbilical cord blood derived hematopoietic stem cells to said subject. ### Claim 5 (depends on 1) The method of claim 1, further comprising selecting a subject who is suffering from a lung disorder prior to administering the population of isolated or enriched umbilical cord blood derived hematopoietic stem cells. ### Claim 6 (depends on 2) The method of claim 2, further comprising selecting a subject in need of repair or reconstitution or generation of pulmonary epithelium prior to administering the population of isolated or enriched umbilical cord blood derived hematopoietic stem cells. ### Claim 7 (depends on 3) The method of claim 3, further comprising selecting a subject in need of repair or reconstitution or generation of pulmonary vasculature or pulmonary endothelium prior to administering the population of isolated or enriched umbilical cord blood derived hematopoietic stem cells. ### Claim 8 (depends on 4) The method of claim 4, further comprising selecting a subject in need of repair or reconstitution or regeneration of pulmonary alveoli prior to administering the population of isolated or enriched umbilical cord blood derived hematopoietic stem cells. ### Claim 9 (depends on 2) The method of claim 2, wherein the administration is intrapulmonary administration, systemic administration, or any combination thereof. ### Claim 10 (depends on 9) The method of claim 9, wherein the intrapulmonary administration is intratreacheal or intranasal administration. ### Claim 11 (canceled) ### Claim 12 (canceled) ### Claim 13 (canceled) ### Claim 14 (depends on 2) The method of claim 2, wherein the population of isolated or enriched umbilical cord blood derived hematopoietic stem cells are expanded ex vivo prior to administration to the subject. ### Claim 15 (depends on 2) The method of claim 2, wherein the hematopoietic stem cells are selected based on positive expression of CD34. ### Claim 16 (depends on 2) The method of claim 2, wherein the subject is an intubated subject. ### Claim 17 (depends on 2) The method of claim 2, wherein the subject is an infant or preterm infant. ### Claim 18 (depends on 2) The method of claim 2, wherein the population of isolated or enriched umbilical cord blood derived hematopoietic stem cells are autologous cells. ### Claim 19 (depends on 2) The method of claim 2, wherein the population of isolated or enriched umbilical cord blood derived hematopoietic stem cells are allogeneic cells obtained from one or more donors. ### Claim 20 (depends on 2) The method of claim 2, further comprising administering at least one therapeutic agent. ### Claim 21 (depends on 2) The method of claim 2, further comprising arming the population of isolated or enriched umbilical cord blood derived hematopoietic stem cells with at least one therapeutic agent. ### Claim 22 (depends on 20) The method of claim 20, wherein the at least one therapeutic agent enhances homing, engraftment, or survival of the population of isolated or enriched umbilical cord blood derived hematopoietic stem cells. ### Claim 23 (depends on 20) The method of claim 20, wherein the at least one therapeutic agent comprises a bispecific antibody. ### Claim 24 (depends on 23) The method of claim 23, wherein the bispecific antibody is an antibody specific for CD34 and VCAM-1. ### Claim 25 (canceled) ### Claim 26 (canceled) ### Claim 27 (canceled) ### Claim 28 (canceled) ### Claim 29 (canceled) ### Claim 30 (canceled) ### Claim 31 (canceled) ### Claim 32 (canceled) ### Claim 33 (canceled) ### Claim 34 (canceled) ### Claim 35 (canceled) ### Claim 36 (canceled) ### Claim 37 (canceled) ### Claim 38 (canceled) ### Claim 39 (canceled) ### Claim 40 (canceled) ### Claim 41 (canceled) ### Claim 42 (canceled)